| Issue Date | Title | Author(s) |
| 2025 | Avelumab Maintenance in Patients With Metastatic Urothelial Carcinoma in a Real-Life Expanded-Access Program (Eap) | Tural, Deniz; Ozkan, Oguzcan; Yaslikaya, Sendag; Tatli, Ali Murat; Akdag, Goncaguel; Demir, Hacer; Urun, Yuksel |
| 2023 | Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: a Multicenter Study From the Turkish Oncology Group Kidney Cancer Consortium | Erol, Cihan; Yekeduz, Emre; Tural, Deniz; Karakaya, Serdar; Şentürk Öztaş, Nihan; Uçcar, Gökhan; Kılıçkap, Saadettin; Arslan, Çağatay |
| 2023 | External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (imdc): Results From the Turkish Oncology Group Kidney Cancer Consortium (tkcc) Database | Yekeduz, Emre; Karakaya, Serdar; Erturk, Ismail; Tural, Deniz; Ucar, Gokhan; Oztas, Nihan Senturk; Arikan, Rukiye; Arslan, Çağatay |
| 2024 | Immune Checkpoint Blockade Therapies Efficacy and Toxicity in Patients With Impaired Renal Function in Metastatic Bladder Cancer | Tural, Deniz; Arslan, Cagatay ; Selcukbiricik, Fatih; Olmez, Omer Fatih; Akar, Emre; Erman, Mustafa; Ueruen, Yueksel |
| 2022 | Long-Term Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice. | Tural, Deniz; Arslan, Cagatay ; Selcukbiricik, Fatih; Olmez, Omer Fatih; Erman, Mustafa; Urun, Yuksel; Karadurmus, Nuri |
| 2025 | Navigating Second-Line Therapy in Metastatic Renal Cell Carcinoma: a Comparative Analysis of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors: a Study of Turkish Oncology Group Kidney Cancer Consortium | Aykan, Musa Baris; Bolek, Hatice; Yekeduz, Emre; Sertesen, Elif; Tural, Deniz; Karacin, Cengiz; Urun, Yuksel |
| 2021 | Nivolumab in Metastatic Renal Cell Carcinoma: Results From the Turkish Oncology Group Kidney Cancer Consortium Database | Yekeduz, Emre; Erturk, Ismail; Tural, Deniz; Karadurmus, Nuri; Karakaya, Serdar; Hizal, Mutlu; Arikan, Rukiye; Arslan, Cagatay |
| 2024 | Objective Response Rate Is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors | Tural, Deniz; Arslan, Çagatay ; Selçukbiricik, Fatih; Ölmez, Ömer Fatih; Erman, Mustafa; Ürün, Yüksel; Erdem, Dilek |
| 2024 | Perceptions and Expectations: a Study on Prognostic Perception and Quality of Life in Patients With Metastatic Renal and Bladder Cancer | Bölek, Hatice; Arslan, Çagatay ; Başaran, Mert; Cicin, Irfan; Ozguroglu, Mustafa; Tural, Deniz; Ürün, Yüksel |
| 2024 | Perceptions and Expectations: a Study on Prognostic Perception and Quality of Life in Patients With Metastatic Renal and Bladder Cancer. | Bolek, Hatice; Arslan, Cagatay ; Başaran, Mert; Cicin, İrfan; Ozguroglu, Mustafa; Tural, Deniz; Ürün, Yüksel |
| 2022 | The Relationship Between Pan-Immune Value and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab in the Second Line and Beyond: a Turkish Oncology Group Kidney Cancer Consortium (tkcc) Study | Yekeduz, Emre; Tural, Deniz; Erturk, Ismail; Karakaya, Serdar; Erol, Cihan; Ercelep, Ozlem; Arslan, Cagatay |
| 2022 | The Relationship Between Systemic Immune Inflammation Index and Survival in Patients With Metastatic Renal Cell Carcinomatreated Withtyrosine Kinase Inhibitors | Yucel, Kadriye Bir; Yekeduz, Emre; Karakaya, Serdar; Tural, Deniz; Erturk, Ismail; Erol, Cihan; Ercelep, Ozlem; Arslan, Cagatay |
| 2024 | Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience From the Turkish Oncology Group Kidney Cancer Consortium (tkcc) Database | Bolek, Hatice; Sertesen, Elif; Kuzu, Omer Faruk; Tural, Deniz; Sim, Saadet; Sendur, Mehmet Ali Nahit; Urun, Yuksel; Arslan, Cagatay |
